Theravance Biopharma
TBPH
91 hedge funds and large institutions have $533M invested in Theravance Biopharma in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 35 reducing their positions, and 18 closing their positions.
103% more call options, than puts
Call options by funds: $478K | Put options by funds: $236K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% less funds holding
Funds holding: 94 → 91 (-3)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
23% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 35
26% less capital invested
Capital invested by funds: $722M → $533M (-$189M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$26.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15M |
| 3 |
FAM
Foundation Asset Management
White Plains,
New York
|
+$11.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$7.23M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$18M |
| 2 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
-$14.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$7.13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.78M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$6.09M |
TBPH Hedge Fund Activity: Q3 2014 in Review
91 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2014, worth a combined $533M — down 26% from $722M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TBPH and 15 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 27 added.
The largest buyer was First Manhattan, adding an estimated $26.7M. The largest seller was Iridian Asset Management, cutting an estimated $18M.
- 91 institutional investors held Theravance Biopharma (TBPH) as of Q3 2014, down from 94 in Q2 2014.
- Funds reported $533M of Theravance Biopharma stock for Q3 2014, down 26% quarter-over-quarter.
- 15 funds opened new Theravance Biopharma positions in Q3 2014 and 18 closed out, a net change of -3 holders.
- The largest Theravance Biopharma buyer in Q3 2014 was First Manhattan, an estimated $26.7M added.
- The largest Theravance Biopharma seller in Q3 2014 was Iridian Asset Management, an estimated $18M sold.
Based on aggregated 13F filings for Q3 2014.